All relevant data are within the paper and its Supporting Information file. All sequence data files are available from the NCBI database (accession number: KF026059-KF026220; KT020928-KT020935).

Background {#sec001}
==========

The rapid scale-up of antiretroviral therapy (ART) in resource-limited countries has dramatically reduced HIV-related mortality and therefore improved quality of life \[[@pone.0141318.ref001], [@pone.0141318.ref002]\]. Contrary to the initial fears, a number of reports have documented successful short-term outcomes of ART \[[@pone.0141318.ref003], [@pone.0141318.ref004]\] due to many factors such as improved adherence \[[@pone.0141318.ref005]--[@pone.0141318.ref007]\]. Nevertheless, scaling up of ART programs have also led to the emergence of antiretroviral drug resistance \[[@pone.0141318.ref006]\]. The exclusive use of clinical and immunological parameters to initiate and monitor ART in this region and the use of drugs with low genetic barrier that only require single point mutation to confer resistance, such as abacavir (ABC), lamivudine (3TC), tenofovir (TDF) and didanosine (ddI) have been associated with the emergence and accumulation of HIV-1 drug-resistant variants \[[@pone.0141318.ref007]--[@pone.0141318.ref009]\]. Consequently, early virological failure remains undetected and patients continue to be on inadequate (or insufficient) regimen until either clinical or immunological failure occurs \[[@pone.0141318.ref008], [@pone.0141318.ref009]\]. In the meantime, resistance mutations may accumulate in the viral pool and in-turn limit future treatment options \[[@pone.0141318.ref010]\], enhance disease progression \[[@pone.0141318.ref011], [@pone.0141318.ref012]\] and may be transmitted to other individuals \[[@pone.0141318.ref010]\]. High level and complex profile of HIV-1 drug resistance mutations including Q151M and thymidine analogue mutations (TAMs) in individuals with first-line ART failure \[[@pone.0141318.ref008], [@pone.0141318.ref009], [@pone.0141318.ref013], [@pone.0141318.ref014], [@pone.0141318.ref015], [@pone.0141318.ref016]\] and increased prevalence of transmitted drug resistance (TDR) mutations have been reported in recent years \[[@pone.0141318.ref017], [@pone.0141318.ref018], [@pone.0141318.ref019], [@pone.0141318.ref020], [@pone.0141318.ref021]\], despite more promising initial observations from Africa \[[@pone.0141318.ref004], [@pone.0141318.ref006], [@pone.0141318.ref013]\].

In Ethiopia increasing prevalence of TDR with time after the roll-out of ART \[[@pone.0141318.ref018], [@pone.0141318.ref019]\], the late presentation of patients in the course of HIV infection and the use of WHO clinical and immunological parameter without HIV viral-load monitoring and drug resistance testing could be associated with delayed switching and consequent accumulation of resistance mutations, as it has been observed in other African countries \[[@pone.0141318.ref001], [@pone.0141318.ref008], [@pone.0141318.ref009]\]. This study therefore aimed to determine and characterize the incidence and pattern of acquired drug resistance mutations after a median time of 30 months (IQR, 27--38) on ART in a prospective cohort of HIV-1 subtype C infected patients with known baseline data \[[@pone.0141318.ref018]\].

Methods {#sec002}
=======

Study design {#sec003}
------------

Patient's inclusion and exclusion criteria have already been described \[[@pone.0141318.ref018]\]. Briefly, HIV-1 chronically infected treatment naïve patients above 18 years of age and seeking care and treatment were consecutively recruited at Gondar University Hospital, Northwest Ethiopia in 2008/2009. Patients were excluded if they were pregnant or had taken single dose nevirapine (NVP) for prevention of mother to child transmission (PMTCT) or patients with known chronic illness or any previous ART use. In this prospective cohort study the long term clinical, immunological and virological outcomes of ART was examined and incidence of acquired drug resistance mutations was determined by the median time of 30 months on ART.

Treatment and patients monitoring {#sec004}
---------------------------------

Patients were evaluated with a standardized form at enrolment and diagnosed based on the WHO criteria of AIDS-defining conditions as described earlier \[[@pone.0141318.ref018]\]. The patients received care and treatment according to the national HIV treatment guideline and were monitored according to the WHO recommendations. First line ART included zidovudine (ZDV), 3TC, stavudine (D4T), nevirapine (NVP), and efavirenz (EFV), permitting four alternative treatment regimens: D4T+3TC+NVP; D4T+3TC+EFV; ZDV+3TC+NVP; or ZDV+3TC+EFV. For second line therapy, the nucleoside backbone waschanged to ABC, TDF, ddI or ZDV (if not used in first-line therapy); and, in addition, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) NVP or EFV was replaced by one of the boosted protease inhibitors (PIs) lopinavir (LPV/r), saquinavir (SQV/r) or indinavir (IND/r). Although D4T has been omitted from ART recommendations because of its side effects in 2008, it is still used extensively in Ethiopia.

Assessment of adherence {#sec005}
-----------------------

As per the routine clinical practice and the protocol of this cohort each patient underwent an adherence counselling before initiation of ART and at their health care visits every three months. Consecutively, self-reported adherence to ART was assessed by asking the last time the patient forgot to take therapy in four weeks time (response options include "never," "yesterday," "last week," and "more than 1 week but less than three weeks ago"). Then, an estimate of patient\'s current adherence to antiretroviral therapy (as "optimal," "suboptimal," and "absent") was made. Patients who reported that they had not forgotten a dose the day prior to their visit and never forget doses were categorized as optimal (theoretical adherence level of at least 95%) \[[@pone.0141318.ref005]\].

Blood collection {#sec006}
----------------

Blood samples was collected in vacutainer tubes containing ethylene diamine tetraacetic acid (EDTA) at baseline, every 6 months (for CD4^+^ T cells count only) and at last by a median time of 30 months on ART (IQR, 27--38). Plasma was separated by centrifugation and stored at-40°C utile used.

Laboratory investigations {#sec007}
-------------------------

Sample collection and preparation, CD4^+^ T cells count, HIV-1 RNA extraction, pol gene amplification and sequencing were done as described previously \[[@pone.0141318.ref018]\]. In brief, CD4^+^ T cells count was measured every 6 months using the FACSCount flow cytometer (Becton Dickinson, San Jose, CA, USA) following the manufacturer's protocols. Immunological failure was defined as failure to achieve a CD4^+^ T cells gain of at least 50 cells above pre-therapy level or having an absolute CD4^+^ T cells count of less than 100 cells/mm^3^ after one year of therapy. HIV viral load was measured at baseline (N = 220) and after a median time of 30 months on ART (N = 127) using Abbott m2000rt Quantitative RealTime HIV-1 assay (Abbott Molecular, Des Plaines, IL, USA) with a lower detection limit of 40 copies/ml.

Although, WHO defines virological failure using viral load cut-offs of \>1000 copies/ml based on two consecutive viral load measurement after 3 months with adherence support, there is no standardized reporting of virologic failure since 3 months may not enough for full viral suppression, and since resistance mutations could be detected in samples with VL of as low as 300 copies/mL and not in patients with viral load of \>1000 copies/ml. Thus, in this study, virological failure is defined as HIV RNA \> 400 copies/mL in single plasma sample and viral load between 40 and 400 copies/ml was defined as low-level viraemia (LLV). HIV genotyping for detection of drug resistance was done at baseline and after a median time of 30 months on ART (N = 127). Viral cDNA was amplified by nested PCR using outer primers yielding a 1757 base pairs (bp) amplicon and subsequently by the inner primers yielding a 1389 bp amplicon covering the entire protease (PR) and partial (76%) reverse transcriptase (RT) enzymes following an in-house protocol. The amplified HIV-1 viral gene was sequenced using BigDye Terminator Cycle Sequencing kit (Applied Biosytems, Waltham, MA, USA). Genotypic drug resistance mutations were interpreted according to the Stanford University drug resistance database (<http://hivdb.stanford.edu>) and the 2014 IAS mutation list \[[@pone.0141318.ref022]\]. HIV-1 subtype was determined by using the REGA HIV-1 Automated Subtyping Tool version 2 (<http://www.bioafrica.net>). Nucleotide sequences are deposited in National Centre for Biotechnology Information (NCBI), USA GenBank (Accession Number before initiation of ART: KF026059-KF026220; By the end of 30 months on ART: KT020928-KT020935).

Statistical analysis {#sec008}
--------------------

To identify potential risk factors associated with virologic failure, a bivariable and multivariable logistic regression analysis were conducted by the end of 30 months. Variables included were age, sex, baseline CD4^+^ T cells count, baseline HIV viral load, WHO clinical stage, baseline drug resistance mutations, level of adherence and the type of ART (NVP versus EFV containing). Differences between viraemic and non-viraemeic groups were tested using the Pearson Chi-square test, the student's t-test and the Fisher's exact test, as appropriate. A P-value of less than 0.05 was considered statistically significant.

Ethical approval {#sec009}
----------------

The study protocol and design including the consent procedures were approved by the University of Gondar Ethical Review Committee (RPO/55/291/00). Patients were managed following the national guideline. Written informed consent was obtained from all study subjects and documented in Research Office of the University.

Results {#sec010}
=======

Cohort characteristics {#sec011}
----------------------

The baseline characteristics of the patients at enrolment were described earlier \[[@pone.0141318.ref018]\]. In brief, HIV genotypic drug resistance testing was performed in 160 pre-ART plasma samples and on the basis of the WHO transmitted drug resistance surveillance mutations list ([S1 Table](#pone.0141318.s001){ref-type="supplementary-material"}), transmitted HIV drug resistance mutations were identified in 21 (13.12%) of the samples. All except to 2 isolates were found to be HIV-1C. Of 220 patients enrolled, 140 patients were on ART by median time of 30 months (IQR, 27--38) but this study has end viral load result for 127 patients. Thus, the results below are for these 127 patients. The cohort profile is summarized in [Fig 1](#pone.0141318.g001){ref-type="fig"}.

![Cohort profile.\
Of the 220 subjects enrolled in the study 63.6% (140/220) were on ART and blood collection for HIV DR was successful in 127 patients; Confirmed death: 12.7% (28/220); overall death including true loss: 27.3% (60/220); True loss: 14.5% (32/220).](pone.0141318.g001){#pone.0141318.g001}

Virological outcomes {#sec012}
--------------------

By on treatment analysis (including patients with both baseline and median time of 30 months virological data), 88% (112/127) of the patients achieved viral suppression with HIV RNA levels ≤ 400 copies/ml of whom 74% (83/112) had undetectable HIV RNA level ([Table 1](#pone.0141318.t001){ref-type="table"}). The median (IQR) baseline HIV viral load for 127 patients was 27, 137 copies/ml (4273--133319). Among the 15 patients with viral loads of above 400 copies/ml, 11 met the WHO virological failure criteria of viral loads of \>1000 copies/ml. However, most of the patients (13/15) with virological failure and accumulated drug resistance mutations had not met the WHO clinical and immunologic failure criteria and continued the failing regimen. Moreover, in 2 patients with viral loads \< 5000 copies/ml, drug resistance associated mutations were detected. In two patients with HIV RNA of 21, 878 and 97, 724 copies/ml, accumulated drug resistance mutations were not observed ([Table 1](#pone.0141318.t001){ref-type="table"}). There was no significant difference in the proportion of patients with baseline CD4^+^ T cells counts of \> 200 cells/mm^3^ with virological failure compared with those with a baseline CD4^+^ T cells count of ≤ 200 cells/mm^3^. The median HIV RNA level among viremic patients at 30 months was not significantly different among those on NVP and EFV (906 copies/ml (525--42986) versus 2198 copies/ml (1545--23389); P \> 0.05).

10.1371/journal.pone.0141318.t001

###### Characteristics of the patients classified as non viremic or viremic after a median time of 30 months on ART (upper) and median CD4 T cell and RNA values (lower).

![](pone.0141318.t001){#pone.0141318.t001g}

  Characteristics                                 Non viremic[\*](#t001fn001){ref-type="table-fn"} (n = 112)   Viremic[^¶^](#t001fn002){ref-type="table-fn"} (n = 15)
  ----------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------
  Gender                                                                                                       
   Male                                           48 (42.8)                                                    6 (40)
   Female                                         64 (57.2)                                                    9 (60)
  WHO stage at ART initiation                                                                                  
   Stage I/II                                     40 (35.7)                                                    4 (26.7)
   Stage III/IV                                   72 (64.3)                                                    11 (73.3)
  CD4^+^ T cell count at baseline                                                                              
   \<200 cells/ mm^3^                             62 (55.4)                                                    7 (46.7)
   ≥200 cells/ mm^3^                              50 (44.6)                                                    8 (53.3)
  CD4^+^ T cell counts at 30 months of ART                                                                     
   \<200 cells/ mm^3^                             6 (5.4)                                                      3 (20.0)
   ≥200 cells/ mm^3^                              106 (94.6)                                                   12 (80.0)
  First line ART                                                                                               
   3TC + D4T + NVP                                52 (46.4)                                                    6 (40.0)
   3TC + D4T + EFV                                21 (18.8)                                                    2 (13.3)
   3TC + AZT + NVP                                27 (24.1)                                                    3 (20.0)
   3TC + AZT + EFV                                12 (10.7)                                                    4 (26.7)
  Median (IQR) age \[Years\]                      33 (18--62)                                                  33.8 (23--58)
  Median (IQR) CD4^+^ T cells/mm^3^at baseline    204 (26--203)                                                170 (75--229)
  Median (IQR)CD4^+^T cells/mm^3^ at 30m of ART   365 (259--434)                                               387 (299--426)
  Median (IQR) HIV RNA level at baseline          57328 (20481--172442)                                        19059 (5754--51833)
  HIV RNA at 30 months of ART                                                                                  
   Undetectable                                   83 (74.1)                                                    0
   1--40                                          6 (5.4)                                                      0
   41--400                                        23 (20.5)                                                    0
   401--5000                                      0                                                            5 (33.3)
   \>5000                                         0                                                            10 (66.7)
  Median follow up time (IQR) \[months\]          30.0 (26--36)                                                31.0 (25--35)

\* HIV RNA \< 400 copies/ml;

^¶^HIV RNA ≥ 400 copies/ml;

3TC (lamiduvine), D4T (stavudine), ZDV (zidovudine), TDF (tenofovir), EFV (efavirenz), NVP (nevirapine); IQR (Inter quartile range)

HIV genotyping drug resistance {#sec013}
------------------------------

Genotyping was successfully determined in 8 of the 15 patients with HIV RNA ≥ 400 copies/ml. Amplification failures were due to low viral loads (ranging from 442 to 1886 copies/ml) probably representing virological blips. Accumulation of drug resistance mutations in RT region selected during treatment was observed in 6 of 8 patients ([Table 2](#pone.0141318.t002){ref-type="table"}). Briefly, 6/8 patients on 3TC developed resistance to 3TC, 2/3 patients on EFV developed resistance to EFV and NVP, 3/5 patients on NVP developed resistance to NVP and 2/5 patients on NVP developed resistance to EFV within 30 months of ART exposure. The most frequent NRTIs resistance associated mutations were the lamivudine-induced M184V mutation (n = 4) and K65R (n = 1). The NNRTIs resistance associated mutations V106M and K103N conferring resistance to EFV and NVP were found in 1 and 2 patient/s, respectively. Other NNRTIs associated mutations Y181S, Y188L, V90I, K101E and G190A were observed in one patient each. Dual-class resistance to NRTIs and NNRTIs were detected in 4 patients with frequent combination of M184V and NNRTI resistance associated mutations. Despite the extensive use of thymidine analogues (TA) like AZT or D4T, TAMs and mutation at codon 151 (Q151M) were not observed. Moreover, major drug resistance mutations on PR region were not detected. However, in all the 8 patients, naturally occurring minor mutations/polymorphic changes at PR region (positions M36I, R41K, H69K, L89M, and I93L) were observed. These mutations already existed in the baseline sequence data.

10.1371/journal.pone.0141318.t002

###### Acquired antiretroviral drug resistance mutations among subtype C Ethiopian patients after a median time of 30 months on ART.

![](pone.0141318.t002){#pone.0141318.t002g}

                   CD4^+^ T cells   HIV RNA   Baseline ART   Time on ART   NRTI           NNRTI                                       
  --------- ------ ---------------- --------- -------------- ------------- -------------- ------- ------- ------------------ -------- ---------------
  5622--2   51/M   250              391       26,915         19,952        3TC+D4T+EFV    25      M184V   3TC, FTC           K103N    EFV, NVP
  5593--2   28/M   401              449       14,791         2,511         3TC+D4T+EFV    35      M184V   3TC, FTC           K103N    EFV, NVP
                                                                                                                             V106M    EFV, NVP, ETR
  5685--2   25/F   229              393       26, 9153       91,201        3TC+D4T+NVP    29      None    \-                 Y181SY   NVP
  5524--2   38/M   8                276       9,120          91,201        3TC+D4T+NVP    33      K65R    3TC,DDI,FTC, TDF   Y188L    EFV, NVP
  5603--2   25/F   32               270       158            4,786         3TC+D4T+NVP    29      M184V   3TC, FTC           V90I     EFV, NVP, ETR
                                                                                                                             K101E    EFV, NVP, ETR
                                                                                                                             G190A    EFV, NVP, ETR
  5476--2   29/F   199              281       26,302         53,703        3TC+D4T+EFV    35      M184V   3TC, FTC           None     \-
  5708--2   38/F   274              319       1,071          26,915        3TC+D4T +NVP   29      None    \-                 None     \-
  5591--2   30/M   32               299       5,754          97,923        3TC+D4T+NVP    31      None    \-                 None     \-
  5542--2   42/F   75               474       33,414         442           3TC+D4T+NVP    28      None    \-                 None     \-
  5776--2   40/M   191              426       80,013         553           3TC+D4T+NVP    32      None    \-                 None     \-
  5666--2   38/F   157              387       51,833         889           3TC+D4T+NVP    36      None    \-                 None     \-
  5684--2   50/F   95               416       103,443        1,570         3TC+D4T+EFV    34      None    \-                 None     \-
  5726--2   40/F   170              383       19,059         1,886         3TC+D4T+EFV    32      None    \-                 None     \-
  5573--2   51/M   112              463       11,433         871           3TC+D4T+NVP    30      None    \-                 None     \-
  5635--2   35/M   211              301       5,635          1,471         3TC+D4T+EFV    29      None    \-                 None     \-

Age: in years; F: Female, M: Male; CD4^+^ T in cells/mm^3^; HIV RNA in copies/ml; Before: Before ART (baseline); After: After initiation of ART; Time on ART in months; NRTI (Nucleoside RT inhibitors): 3TC (lamiduvine), ddI (didanosine), d4T (stavudine), FTC (emtricitabine), TDF (tenofovir), ZDV (zidovudine); NNRTI (non-nucleoside RT inhibitors): EFV (efavirenz), ETR (etravirine), NVP (nevirapine); Amino acids: A (alanine), E (glutmatate), G (glucine), K (lysine), L (leucine), M (methionine), N (asparganine), S (serine), V (valine), Y (tyrosine)

Clinical and immunological outcomes {#sec014}
-----------------------------------

By the median time of 30 months on ART, 18 out of 127 patients (14.2%) were non-adherent at least once. The main reasons for non-adherence were health related problems (9/18) and drug side effects (5/18). Accordingly, treatment switching was made (3 due to clinical failure, 6 due to immunological failure and 4 due to drug associated toxicity: 3 patients stopped AZT due to anaemia, 1 stopped EFV due to neuropsychiatric disorder and 1 stopped d4T due to neuropathy and lipodystrophy) at a median time of 61 days after initiation of ART. All the patients were on appropriate ART regimen as per the National ART guideline and were clinically asymptomatic. The median CD4^+^ T cells count of the 127 patients at baseline was 194 (IQR, 25--229) cells/mm^3^ and progressively increased over time ([Fig 2](#pone.0141318.g002){ref-type="fig"}). The rate of CD4^+^ T cells count increased significantly in the first 12 months period (+183 cells/mm^3^) exceeding the rate of the following 24 months (+81 cells/mm^3^, P \<0.01, 95% CI, 69--91). The rate of CD4^+^ T cells recovery was not different among patients who were taking NVP versus EFV based regimen (+211 vs + 217 cells/mm^3^; P = 0.14).

![Immunological restoration among HIV-1C Ethiopian patients (N = 127 at each time point) during 30 months of ART.](pone.0141318.g002){#pone.0141318.g002}

Factors associated with virological failure {#sec015}
-------------------------------------------

In both bivariable and multivariable analyses, baseline severe immunosuppression (defined as CD4^+^ T cells count of \< 50 cells/mm^3^) and baseline HIV RNA of \>100,000 copies/ml were not identified as risk factors for virological failure at 30 months. The presence of baseline transmitted drug resistance mutations was not a risk factor for virological failure by the median time of 30 months on ART, either. However, 14 of 21 patients with baseline transmitted drug resistance associated mutations were lost to follow-up and only 7 out of 21 achieved viral suppression. Other demographic predicting factors (age, sex, WHO clinical stages, type of ART regimen) were also not significant risk factors for virological failure at 30 months ([Table 3](#pone.0141318.t003){ref-type="table"}). However, treatment non-adherence was identified as significant risk factor for virological failure at 30 months (OR 5.11:95%CI; 2.11--21.00, P = 0.02).

10.1371/journal.pone.0141318.t003

###### Factors associated with virological failure by 30 months of ART.

![](pone.0141318.t003){#pone.0141318.t003g}

  Variables                                                            Crude                Adjusted                        
  -------------------------------------------------------------------- -------------------- ---------- -------------------- ------
  Gender                                                                                                                    
   Male                                                                Reference                                            
   Female                                                              1.23 (0.56--2.57)    0.09       1.37 (0.65--3.17)    0.12
  Age (years)                                                          0.91 (0.81--1.12)    0.18       0.94(0.83--1.17)     0.27
  Baseline WHO clinical stage                                                                                               
   Stage I                                                             Reference                                            
   Stage II                                                            2.13(0.63--6.73)     0.13       1.89(0.54--6.17)     0.19
   Stage III                                                           1.38 (0.48--4.72)    0.17       3.81 (0.81--4.12)    0.07
   Stage IV                                                            0.88 (0.31--4.63)    0.22       1.28 (1.74--9.19)    0.8
  Baseline CD4^+^ T cell counts[\*](#t003fn001){ref-type="table-fn"}                                                        
   \>200                                                               Reference                                            
   50--200                                                             1.49 (0.19--4.13)    0.66       1.58(0.43--5.34)     0.34
   \<50                                                                1.74 (0.37--4.39)    0.69       1.83(0.44--5.76)     0.39
  Baseline HIV RNA level[\*\*](#t003fn002){ref-type="table-fn"}                                                             
   \<10, 000                                                           Reference                                            
   10, 001--100, 000                                                   1.31(0.59--4.79)     0.33       2.18 (0.79--5.94)    0.36
   \>100, 000                                                          0.46(0.11--6.70)     0.13       0.93 (0.62--7.21)    0.12
  First line ART                                                                                                            
   NVP containing regimen                                              Reference                                            
   EFV containing regimen                                              2.33 (0.55--3.37)    0.4        1.36 (0.93--3.17)    0.31
  Transmitted drug resistance                                                                                               
   No                                                                  Reference                                            
   Yes                                                                 1.17 (0.29--3.88)    0.35       1.77 (0.43--5.41)    0.08
  Level of adherence                                                                                                        
   Optimal                                                             Reference                                            
   Sub-optimal                                                         1.48 (0.66--9.49)    0.15       2.83 (0.73--9.03)    0.6
   Absent                                                              4.78 (2.53--11.17)   0.01       5.11 (2.11--21.00)   0.02

\*CD4^+^ T cells count in cells/mm^3^;

\*\*HIV RNA level: copies/ml

Discussion {#sec016}
==========

This is the first report describing the incidence and pattern of acquired antiretroviral drug resistance mutations among HIV-1C infected patients in a prospective cohort study from the Horn of Africa with in a median time of 30 months on ART. The 12% virological failure (≥400 copies/ml) in the current study is comparable with recent cross-sectional studies from the region \[[@pone.0141318.ref004], [@pone.0141318.ref008], [@pone.0141318.ref013], [@pone.0141318.ref023]\] and WHO suggested targets of virological suppression were achieved in at least 70% of patients 12 months after ART initiation \[[@pone.0141318.ref017]\]. However, recent studies from some African countries had reported a high level of virological failure after a weighted median time of 25 months on ART \[[@pone.0141318.ref013], [@pone.0141318.ref024], [@pone.0141318.ref025]\]. Thus, compared with the few available data on the long term effect of ART our finding showed low rate of virological failure which could be due to the optimal adherence level of the patients (85.8%) and in the setting \[[@pone.0141318.ref005]\] and suggests that ART in the setting can sustain virological efficacy for a substantial length of time if an optimal adherence on treatment is achieved. However, these results may not fully represent other public HIV clinics in Ethiopia.

The emergence and accumulation of acquired antiretroviral drug resistance mutations in 6 of 8 patients ([Table 2](#pone.0141318.t002){ref-type="table"}) reflect the expected pattern of acquired drug resistance while using the standard first line ART attributed to the 3TC, NVP or EFV pressure. The findings were similar to that of subtype C sub Saharan African isolates \[[@pone.0141318.ref003], [@pone.0141318.ref013]\] and other subtypes in resource-limited settings \[[@pone.0141318.ref026], [@pone.0141318.ref027]\]. The K65R known to be selected faster in subtype C was observed in one patient who has been taking 3TC, D4T and EFV. This is very low compared to similar studies among subtype C isolates from six sub Saharan African countries \[[@pone.0141318.ref024]\] but consistent with recent study from South Africa \[[@pone.0141318.ref028]\]. This could be due to the recent availability of TDF in Ethiopia \[[@pone.0141318.ref004], [@pone.0141318.ref018]\] and because of the fact that none of the patients were under TDF. Among the NNRTIs mutations, K103N, V106M, and G190A conferring resistance to EFV and NVP; EFV, NVP and ETR; and EFV and NVP, respectively were observed in 2 and 1 patient each similar to recent data from various African countries \[[@pone.0141318.ref004], [@pone.0141318.ref013], [@pone.0141318.ref018], [@pone.0141318.ref025]\]. Four out of six patients failed as a result of M184V and NNRTIs mutation. Five out of 6 patients had NNRTIs mutations probably suggesting that resistance to NNRTIs are the initial event in failure of regimens containing EFV or NVP in the setting. Despite the extensive use of thymidine analogues like AZT or D4T in Ethiopia and unlike previous similar studies \[[@pone.0141318.ref003], [@pone.0141318.ref013], [@pone.0141318.ref027]--[@pone.0141318.ref029]\], TAMs characterized by the mutations M41L, L210W, T215Y (TAM-path 1) and D67N, K70R, T215F, K219Q/E (TAM-path 2) were lacking in the current study indicating a recent period of virological failure. This also supports previous reports that mutations correlated with TAMs pathways are infrequent in non B subtypes compared to subtype B \[[@pone.0141318.ref004], [@pone.0141318.ref017]--[@pone.0141318.ref025], [@pone.0141318.ref026]--[@pone.0141318.ref029]\]. The absence of major drug resistance mutations in PR region might be a reflection of late introduction and limited access of this drug class in the country \[[@pone.0141318.ref004], [@pone.0141318.ref018]\].

Despite the small number of sequences, the spectrum of drug resistance mutations observed in this study was not complex which is consistent with a recent study from Rwanda \[[@pone.0141318.ref030]\]. However, the occurrence of virological failure and resistance mutations in most of the patients without reaching the WHO clinical and immunological criteria that presently apply to Ethiopia and other developing countries suggests the need for virological monitoring and targeted drug resistance testing in the region. These patients also continued the failing regimen which would limit future treatment option and may result in deleterious consequences if transmission to newly infected individuals occurs. The low level viraemia (40--400 copies/ml) observed in a single sample of 23 clinically asymptomatic patient with immune recovery, supports previous findings that reported transient episodes of low level viraemia do not generally reflect negative clinical consequence \[[@pone.0141318.ref004], [@pone.0141318.ref031], [@pone.0141318.ref032]\] and show the presence of virological blips rather than virological failure. However, some may remain suppressed and others may develop virological failure if tested later.

In this prospective cohort, progressive immune restoration was observed over time similar to previous reports \[[@pone.0141318.ref004], [@pone.0141318.ref033]--[@pone.0141318.ref034]\]. It is, to be noted however, that after nearly 3 years of ART about one fifth of the patients remained below the lower threshold level (less than 350 CD4^+^ T cells/mm^3^). This could be due to the natural low CD4^+^ T cells count among Ethiopians \[[@pone.0141318.ref004], [@pone.0141318.ref035], [@pone.0141318.ref036]\], late ART initiation with low baseline CD4^+^ T cells count, slow recovery rate of CD4^+^ T cells among Africans \[[@pone.0141318.ref037]\] or may also be due to immune activation which results in CD4^+^ T cells count depletion independent of HIV RNA load \[[@pone.0141318.ref038], [@pone.0141318.ref039]\].

In conclusion, despite the obvious small number of sequences the findings suggest that in resource limited settings ART can sustain virological efficacy for a substantial length of time and also enhance immunological recovery if supplemented with adherence counselling ensuring an optimal adherence level. However, the 12% virological failure and resistance mutations observed in the absence of the WHO clinical and immunological criteria that presently apply to developing countries suggest the need for affordable virological monitoring and targeted drug resistance testing assays in the region.
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